

PRESS RELEASE

European Association of Urology (EAU)

28th Annual EAU Congress

For immediate release

**Study confirms difference in radical prostatectomy outcomes between surgeons**

Milan, 18 March 2013- New evidence from Sweden confirms previous studies which suggest that functional outcomes after radical prostatectomy may vary between surgeons, especially in relation to continence. However, the group found no evidence of heterogeneity in potency-related outcomes.

The results of this investigation, to be presented at the 28th Annual EAU Congress, aimed of to examine between surgeon variation with regards to oncological and patient-reported functional outcomes in one European centre.

The study included 1280 men who underwent open radical prostatectomy performed by one of nine surgeons at an academic institution in Sweden between 2 January 2001 through 16 July 2008.

Biochemical recurrence was defined as a prostate-specific antigen (PSA) value > 0.2 ng/ml with at least one confirmatory rise. The scientists measured functional outcomes preoperatively and postoperatively 18 months after the procedure by patient-administered questionnaires. Multivariate random effect models were used to evaluate heterogeneity between surgeons, adjusting for case mix – which included age, PSA, pathological stage and grade - year of surgery and surgical experience.

Of 635 men potent at baseline, 606 provided data at 18 months, of whom 100/606 (17%) were potent (nerve-sparing and non-nerve-sparing surgery), suggesting the absence of heterogeneity between surgeons (p=0.5).

The continence rate at 18 months was 85%, revealing statistically significant heterogeneity between surgeons (p=0.002). There was evidence of an unexpected negative correlation between the surgeons’ adjusted probabilities of potency and continence at 18 months. At the same time, the researchers did not find any association between surgeons’ adjusted probabilities of functional recovery and 5-year probability of freedom from biochemical recurrence.

“Surgeon heterogeneity suggests that at least some patients are receiving suboptimal care,” write the authors. “Quality assurance measures should be considered to identify and correct suboptimal treatments to ensure patients receive optimal care.”

###

**For further information please contact:**

Ivanka Moerkerken

i.moerkerken@uroweb.org

Tel: +31 (0) 26 389 0680

**Notes to editors**

**About prostate cancer**

Prostate cancer is still a major health concern in the Western male population. It is the most common male malignancy in most European countries with 346,000 new cases diagnosed each year in Europe. Research efforts have increased steadily over the past two decades.

**About the European Association of Urology**

The EAU represents the leading authority within Europe on urological practice, research and education. Over 16,000 medical professionals have joined its ranks and help to create forward-looking solutions for continuous improvement, professional growth and knowledge sharing. The EAU delivers training, stimulates research and broadcasts information. The EAU’s scientific publications encourage discussion and its expert recommendations guide urologists in their every-day practice.

**Reference**

S. Carlsson, et al., “*Effects of surgeon variability on oncological and functional outcomes in a population-based setting*,” Abstract Nr: 808; 28th Annual EAU Congress, 15 to 19 March 2013; Milan, Italy.